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Background: Rhipicephalus (Boophilus) microplus is the main ectoparasite affecting livestock worldwide. For a
successful parasitism, ticks need to evade several immune responses of their hosts, including the activation of the
complement system. In spite of the importance of R. microplus, previous work only identified one salivary molecule
that blocks the complement system. The current study describes complement inhibitory activities induced by
R. microplus salivary components and mechanisms elicited by putative salivary proteins on both classical and
alternative complement pathways.
Results: We found that R. microplus saliva from fully- and partially engorged females was able to inhibit both
pathways. Saliva acts strongly at the initial steps of both complement activation pathways. In the classical pathway,
the saliva blocked C4 cleavage, and hence, deposition of C4b on the activation surface, suggesting that the
inhibition occurs at some point between C1q and C4. In the alternative pathway, saliva acts by binding to initial
components of the cascade (C3b and properdin) thereby preventing the C3 convertase formation and reducing
C3b production and deposition as well as cleavage of factor B. Saliva has no effect on formation or decay of the C6
to C8 components of the membrane attack complex.
Conclusion: The saliva of R. microplus is able to inhibit the early steps of classical and alternative pathways of the
complement system. Saliva acts by blocking C4 cleavage and deposition of C4b on the classical pathway activation
surface and, in the alternative pathway, saliva bind to initial components of the cascade (C3b and properdin)
thereby preventing the C3 convertase formation and the production and deposition of additional C3b.
Keywords: Rhipicephalus (Boophilus) microplus, Saliva, Complement inhibition, Classical pathway, Alternative
pathwayBackground
The cattle tick Rhipicephalus (Boophilus) microplus is
the primary ectoparasite affecting livestock worldwide
leading to considerable economic losses for cattle farm-
ing in tropical and subtropical areas of world [1–3]. This* Correspondence: rnaraujo@icb.ufmg.br
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spp. and Anaplasma spp., that affect cattle farming [4].
While feeding, ticks, including R. microplus, secrete an
arsenal of bioactive molecules that modulate the host
immune system and haemostasis, which aids in the hae-
matophagy and in the transmission of pathogens [5–7].
Indeed, ticks have salivary molecules that are capable of
inhibiting the complement system [8–11]. Since the first
description of complement inhibition by tick saliva in
Ixodes dammini (syn. of I. scapularis, see [12]) [13], sev-
eral tick salivary anti-complement molecules have been
described [10, 14–16]. In spite of its importance, to datele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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saliva on the complement system [17].
The complement system is one the first lines of de-
fence from vertebrate hosts and can be triggered by
three pathways: the classical, the lectin and the alterna-
tive pathways [18]. The classical pathway is triggered
when C1q binds to the Fc region of antigen-bound IgM
or IgG antibodies. Each C1rC1s dimer, composed of one
C1r and one C1s subunit, binds to one C1q to form a
C1 complex, which cleaves C4 and C2 to give C4b and
C2a. These attach to the activation surface to form the
C4bC2a enzyme (otherwise known as C3 convertase of
the classical pathway). The C3 convertase cleaves multiple
C3 molecules into C3b and C3a. C3b then associates with
C4b from the C3 convertase to form the C5 convertase of
the classical pathway (C4bC2aC3b) [19, 20].
The lectin pathway shares components with the classical
pathway, but instead of antibodies and C1, the cascade is
initiated by the binding of mannose-binding lectins (MBL)
or ficolins to highly glycosylated pathogen-associated mo-
lecular patterns (PAMPs) present on the surface of a wide
range of pathogens [21, 22].
Differently from the classical pathway, the alternative
pathway is constantly activated and proceeds unless
inactivated by plasma or membrane-bound regulatory
molecules. The process is triggered when C3b, which is
always present in small amounts in the serum and extra-
cellular fluids from C3 hydrolysis, covalently binds to ac-
tivation surfaces and to fB that is subsequently cleaved
by factor D to give the C3 convertases of the alternative
pathway (C3bBb). These, in turn, produce additional
C3b molecules thereby amplifying the cascade [20, 23].
The C3 convertase is a labile enzyme stabilized by the
aggregation of one properdin molecule that increases
the half-life of the complex by at least 10-fold [24] and
the ability of surface-bound C3b to interact with fB
[25]. When a second C3b binds to the C3bBb complex,
the alternative pathway C5 convertase is assembled
(C3bBbC3b) [19, 20].
The C5 convertase formed from the three complement
system activation pathways cleaves C5 into C5a and
C5b thereby triggering the assembly of the membrane
attack complex (MAC). Thus, C5b rapidly associates
with C6, C7 and C8, and C9 molecules to form the
C5b6789 or MAC, which is assembled on the surface of
pathogens, thereby forming pores on the lipid bilayer of
membranes [18, 26].
Complement pathways are highly regulated via many
control proteins and intrinsic enzymatic activities that
act mainly by: direct inhibition of serine proteases, decay
and destruction of convertases and control of the MAC
[19]. In addition to pores on lipid membranes, the com-
plement is also an effector of humoral immunity and
inflammation. Organism- or antigen-bound C3b aids inopsonisation and phagocytosis by effector cells in a
process mediated by complement receptors [27, 28]. In
addition, C3a and C5a are strong anaphylatoxins that in-
duce damage by recruiting and stimulating granulocytes
to release tissue-degrading enzymes, pro-inflammatory
mediators and reactive oxygen species [18, 29].
Most of the described tick salivary proteins affecting
the host’s complement system come from tick species
belonging to the genus Ixodes. In addition, most inhibit
the complement alternative pathway by binding to pro-
perdin thus inducing the decay of the C3 convertase and
also dissociating Bb from C3b [15, 16]. Besides inhibiting
the alternative pathway, the Tick Salivary Lectin Pathway
Inhibitor (TSLPI) of I. scapularis is also known to inhibit
the lectin pathway by preventing the binding of MBL
and ficolins to their ligands thus blocking the activation
of the complement cascade [30]. Two other salivary
proteins are known to inhibit the complement pathways:
one (named AamAV422) described in Amblyomma
americanum, which blocks the classical pathway [31],
and another (named OmCI) in the argasid Ornithodoros
moubata [32]. However, the inhibition mechanisms elic-
ited by AamAV422 remain unexplored whereas it is
known that OmCI binds to C5, thereby inhibiting both,
the classical and alternative pathways [32]. Saliva of the
neotropical tick Amblyomma cajennense was also shown
to inhibit the classical pathway; however the inhibitor
was not identified [33]. Recently, a new family of C5
inhibitors was identified with homolog sequences in
the species Rhipicephalus appendiculatus, R. micro-
plus, Dermacentor andersoni and Hyalomma margina-
tum [17]. Members of this family were shown to act
similarly to OmCI, but binding to a different site at the
C5 component.
Efforts towards finding the elusive salivary proteins of
R. microplus affecting the host complement system and
their mechanisms of action may be an important step to
understand the relationship between parasite and host
and to assist the identification of new vaccine targets
against this ectoparasite. Indeed, conventional tick con-
trol is based on the expensive and labor-intensive treat-
ment of animals with acaricides but their improper use
has increased the incidence of acaricide-resistant ticks
[34]. Here we confirmed the complement inhibitor activity
in R. microplus saliva and investigated other mechanisms
elicited by putative salivary proteins on the classical and
alternative complement pathways.
Methods
Obtaining ticks and saliva
Rhipicephalus microplus ticks were collected from nat-
urally infested adult crossbred cattle (Gir × Holstein)
maintained in the Santa Rita Experimental Farm of
the Agricultural Research Company of Minas Gerais
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28'55"S, 44°09'18"W). Fully- (> 4 mm) and partially (< 4
mm) engorged females were carefully detached from cattle
skin, cleaned with distilled water and attached onto a sur-
face with double-sided adhesive tapes. The saliva was ob-
tained by injection of 3 to 6 μl pilocarpine in 2 % PBS
(136.8 mM NaCl; 2.7 mM KCl, 4.76 mM Na2HPO4 and
1.76 mM KH2PO4) into the ventro-lateral region of the
body [14]. Saliva was collected for two hours directly from
the mouthparts of the ticks using a pipette tip followed by
centrifugation (14,000× g for 5 min) and the supernatant
was stored at -80 °C until use. Salivary total protein con-
centration was determined using bovine serum albumin
as standard [35]. Briefly, three replicates of each ali-
quoted saliva were diluted 1:10 in 20 μl distilled water
and added to 200 μl Bradford solution (0.1 % Coomassie
Brilliant Blue G-250, 5 % ethanol and 8.5 % phosforic
acid). After 5 min, the mixture was measured using a
spectrophotometer (UV-1650PC Spectrophotometer,
Shimadzu) at 595 nm.
Classical pathway haemolysis assays
Classical pathway haemolytic assays were carried out
using sheep erythrocytes according to Mendes-Souza
et al. [36], modified from Whaley & North [37]. Fresh
sheep blood suspension (500 μl), conserved in Alsever’s
solution at a ratio of 1:1, was washed three times with
5 ml GHB-EDTA buffer (0.1 % gelatin, 5 mM Hepes,
145 mM NaCl and 10 mM EDTA, pH 7.4) followed by
sensitisation of the erythrocytes with sheep anti-
erythrocyte antibody (1:1,000). The erythrocytes were
washed once with 5 ml of GHB-EDTA buffer and twice
with 5 ml GHB2+ (GHB buffer supplemented with 0.15 mM
CaCl2 and 0.5 mM MgCl2, pH 7.4) by centrifugation at
470× g for 5 min at 4 °C. Erythrocyte concentration was
adjusted to 2 × 108 cells/ml before each experiment.
The haemolytic assays were conducted in a final vol-
ume of 125 μl containing up to 25 μl of tick saliva or sa-
line (15.4 mM NaCl in 100 ml) and 50 μl of normal
human serum (NHS) diluted in GHB2+ buffer at a ratio
of 1:60. Aliquots of the erythrocyte solution (50 μl) were
added to the assays and the reaction was incubated at
37 °C for 30 min. After incubation, the reaction was
stopped by the addition of 500 μl of ice-cold saline.
Haemolysis was measured spectrophotometrically at
414 nm. All assays were carried out in duplicate with at
least three biological replicates. For each experiment,
three different controls (without saliva and with pilocar-
pine) were used as follows: total haemolysis (saline was
substituted by distilled water); positive control (haem-
olysis caused by serum without any sample); and nega-
tive control (without NHS where only spontaneous
haemolysis is present). NHS aliquots (stored at -80 °C)
were submitted to one freezing and thawing cycle andhad their concentration adjusted in order to generate at
least 90 % of the total haemolysis. The results were
expressed as percentage of haemolysis inhibition in rela-
tion to the positive control.
Alternative pathway haemolysis assays
For the alternative pathway, unsensitised rabbit blood
was used as activating surface [36, 37]. Aliquots of fresh
rabbit blood (500 μl) conserved in Alsever’s solution in a
1:1 ratio were washed three times with 5 ml Mg-EGTA
solution (5 mM Hepes, 145 mM NaCl, 100 mM EGTA,
7 mM MgCl2, 0,1 % gelatin, pH 7.4) by centrifugation at
470 g for 5 min at 4 °C. EGTA chelates the divalent cat-
ion Ca2+, but not Mg2+, thereby inhibiting the activation
of the classical pathway and leaving only the alternate
pathway active. The concentration of erythrocytes was
adjusted to 2 × 108 cells/ml as above. The haemolytic as-
says were conducted using 50 μl (1:10) NHS diluted in
Mg-EGTA buffer solution. The other procedures were
similar to that used for the classical pathway described
above.
Enzyme-linked immunosorbent assays for the classical
pathway
The classical pathway assays were performed as de-
scribed before [38]. Each well of a 96-well micro-
plate (Costar®, code 9017) was sensitised with 2 μg
of purified human IgG in 50 μl of carbonate/bicarbon-
ate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6)
by overnight incubation in a humid chamber. IgG was
purified from human serum by affinity chromatog-
raphy using a Protein A-conjugated Sepharose bead
column [39].
The sensitised wells were blocked with 200 μl of
blocking solution 1 (3 % skimmed milk powder in 10
mM Tris, 140 mM NaCl, pH 7.4) followed by the
addition of 200 μl of blocking solution 2 (blocking solution
1 supplemented with 5 mM CaCl2), both incubated for 30
min at room temperature under agitation (150 rpm). After
blocking, the saliva and human serum (1:100) in 100 μl of
sample buffer (5 mM Hepes, 145 mM NaCl, 2 mM CaCl2,
1 mM MgCl2, pH 7.4) were incubated at 37 °C for 30 min
under agitation. Positive and negative controls (similarly
to the haemolytic assays) were also included. The wells
were washed three times with 200 μl of washing solution
(blocking solution 2 with 0.1 % skimmed milk powder) at
room temperature for 2 min under agitation.
The components deposited on the plate surface after
the classical pathway activation were detected using
50 μl/well of specific antibodies diluted in antibody
buffer (10 mM Hepes, 140 mM NaCl pH 7.4) incubated
for 30 min under agitation. The antibodies used are as
follows: goat anti-human C1q (Sigma: C3900), goat anti-
human C5b (Sigma: C3402) and goat anti-human C9
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human C3b (Sigma: C3402) and rabbit anti-human C4b
(Sigma: C3402) diluted at 1:1000. These antibodies were
diluted in antibody solution (10 mM Hepes, 140 mM
NaCl pH 7.4) and incubated for 30 min (150 rpm). Each
well was then washed three times.
Antibodies were detected by the addition of 50 μl/well
of peroxidase-conjugated antibodies (rabbit anti-goat
IgG (Sigma: A5420) diluted at a ratio of 1:2500 or mice
anti-rabbit IgG (Sigma: A1949) diluted at 1:1500) in
antibody solution. After washing, bound components
were developed by addition of 200 μl of peroxidase sub-
strate solution (1 mg/ml O-Phenylene-diamine (Sigma:
P9029), 50 mM sodium citrate, 0.075 % H2O2 (Synth:
P22330) pH 5.5). Absorbance at 450 nm was measured
in a microplate reader (Versamax, Molecular Devices)
every 30 s for 10 (kinetic method) at 37 °C. The data gener-
ated were converted to percentage of deposition according
to the following equation: [(Vmax450nmsample - Vmax450nm
sample solution)/(Vmax450nm NHS - Vmax.450nm sample
solution)] × 100.
Positive controls were considered as 100 % deposition.
The results were expressed as relative percentage inhib-
ition by comparing the deposit levels in the experimental
assays with the deposit levels obtained in the positive
control experiments.
Enzyme-linked immunosorbent assays for the alternative
pathway
Assays for the alternative pathway were performed with
the addition of 100 μl/well of 0.1 % agarose solution and
incubation at 37 °C for 24 h [38]. Saliva and NHS (7:100
ratio) were diluted in up to 100 μl of HMEBN solution
(5 mM Hepes, 7 mM MgCl2, 10 mM EGTA, 5 mg/ml
BSA, 145 mM NaCl, pH 7.4) were incubated for 30 min
at 37 °C under agitation. After incubation, the wells were
washed three times with 200 μl of HMEBN for two min
at room temperature and under agitation. The compo-
nents deposited on the plate surface after the activation
of the alternative pathway were detected using 50 μl/well
of the following specific antibodies: rabbit anti-human
C3b, goat anti-human Bb (Comp Tech: A235), goat anti-
human properdin (Comp Tech: A239), goat anti-human
C5b or goat anti-human C9. Antibodies were diluted at
1:1000 in HN solution (10 mM Hepes, 145 mM NaCl,
0.1 % BSA, pH 7.4) and incubated for 30 min at room
temperature under agitation. After incubation, the wells
were washed as described above and 50 μl of peroxidase-
conjugated mice anti-rabbit IgG antibody or rabbit anti-
goat IgG. Conjugates were diluted at a 1:1500 ratio in HN
solution and incubated for 30 min under agitation at room
temperature. The wells were washed again and 200 μl of
peroxidase substrate solution were added. Absorbance at
450 nm was measured as above.Western blot analysis of complement factors cleavage
The cleavage of C4 in human serum was assessed by
Western blot using the supernatants from the classical
pathway haemolytic assays [40]. Sample aliquots of 25 μl
(saline or 15 μg salivary protein) were used to perform
the classical pathway haemolytic assays as above. Reac-
tions at 0 and 30 min were centrifuged (1,700 g for 1 min)
and 25 μl of the supernatant in reducing and denaturing
buffer (10 % SDS and 5 % β-2-Mercaptoetanol) was ap-
plied on 10 % SDS-PAGE electrophoretic analysis of the
protein content [41]. The proteins in the gels were trans-
ferred to nitrocelulose membranes (Immunobilon-NC,
Millipore) and incubated with goat anti-human C4 (Comp
Tech: A205) diluted using a 1:2000 ratio in PBS/tween-20
for 2 h under agitation. The secondary antibody (rabbit
anti-goat IgG peroxidase-conjugated) was diluted at a ra-
tio of 1:4000 in PBS. Band identification was performed
using the DAB Peroxidase Substrate Kit (Vector Labora-
tories, Burlingame, USA).
The C4 cleavage was also evaluated using purified
components [40]. In 0.5 ml tubes, 0.6 μg of C1s was
combined to 3 μg of C4 and 15 μg of salivary proteins
in 30 μl PBS total volume. Tubes containing C4 alone
were used as negative control while tubes containing
C4 and C1s without saliva were used as positive con-
trol. A tube containing C4 plus saliva was also used as
control to evaluate possible C4 cleavage by salivary pro-
teases. Samples were incubated for 2 h at 37 °C and the
enzymatic activity of C1s was measured by the presence
of a 84 kDa α’ C4 fragment by Western blot as de-
scribed above.
To analyse C3 cleavage, alternative pathway haemolytic
assays were performed and analysed by Western blot as
above except for the antibodies used: goat anti-human C3
(Comp Tech: A213) diluted using a 1:2000 ratio followed by
addition of peroxidase-conjugated rabbit anti-goat IgG di-
luted at a ratio of 1:4000. For B cleavage analysis, the sam-
ples were applied on a native-PAGE and the antibodies used
were goat anti-human factor B (Calbiochem®: 401504) di-
luted 1:1000 and rabbit anti-goat IgG peroxidase-conjugated
diluted at 1:2000 [15].
The cleavage of factor B was also evaluated using puri-
fied complement components [15]. The assay was car-
ried out by combining 0.5 μg factor D with 2 μg fB, 2 μg
C3b and 15 μg of salivary proteins in 30 μl PBS final vol-
ume supplemented with 5 mM MgCl2. Tubes containing
only fB were used as negative control while tubes con-
taining fB, C3b and factor D without saliva were used as
positive control. A control containing fB plus saliva eval-
uated the possible fB cleavage by salivary proteases.
Samples were incubated for 30 min at 37 °C. The en-
zymatic activity of the factor D on factor B was mea-
sured by Western blot visualising a 60 kDa Bb fragment,
as described above.
Silva et al. Parasites & Vectors  (2016) 9:445 Page 5 of 14Quantification of C3bBP formation by ELISA
The C3 convertase precursor (C3bBP) was synthesised
in vitro by combining C3b (Comp tech: A114), factor B
(Comp tech: A135) and properdin (Comp: A139) (modi-
fied from [42]). The wells of 96-well microplates were
coated with 50 μl/well of C3b in PBS and incubated for
12 h at 4 °C in a humid chamber. The C3b-bound wells
were then blocked with 200 μl of PBS/Tween-20 solu-
tion containing 1 % BSA for 2 h at room temperature
under agitation. Afterwards, the wells were washed three
times with washing buffer (8.1 mM Na2HPO4, 1.8 mM
NaH2PO4, 25 mM NaCl, 10 mM MgCl2, 0.05 % Tween-
20, pH 7.4) for 3 min under agitation. After the wash-
ings, up to 50 μl saliva, factor B and properdin in bind-
ing buffer (8.8 mM Na2HP04, 1.8 mm NaH2P04, 0.05 %
Tween-20, 75 mM NaCl, 10 mM MgCl2, 1 % BSA,
pH 7.4) were added to the wells and incubated for 30 min
at 37 °C under agitation followed by one washing cycle.
An antibody mixture (50 μl), containing either anti-fB
or anti-properdin antibody in antibody binding buffer
(8.8 mM Na2HP04, 1.8 mM NaH2P04, 0.05 % tween-20,
25 mM NaCl, 10 mM MgCl2, 1 % BSA) at pH 7.4, was
incubated on the wells for 30 min at room temperature
under agitation. This step was followed by three washes
as described above. A solution (50 μl/well) of rabbit
anti-goat IgG peroxidase-conjugated at a ratio of 1:2000
in antibody solution was added to the wells and incu-
bated for 30 min at room temperature under agitation.
After the washes, components bound to the plate sur-
face were developed with addition of 200 μl of develop-
ing solution. Deposition levels (%) were calculated using
the following equation: [(OD450nmsample - OD450nm
only C3b in wells)/(OD450nmsample without saliva -
OD450nm only C3b in wells)] × 100 and used for statis-
tical analysis.
Binding of R. microplus saliva to components of the
complement alternative pathway
To analyse whether salivary molecules bind to compo-
nents of the complement alternative pathway, 96-well
microplates were coated with 10 μg of R. microplus sal-
ivary protein or 1 % BSA (negative controls) diluted in
50 μl of carbonate/bicarbonate buffer by overnight incu-
bation in a moist chamber at 4 °C. The wells were then
blocked with 200 μl of blocking solution (PBS with 1 %
BSA) and incubated for 1 h at room temperature under
agitation. After blocking, 50 μl of PBS containing 0.2 μg
of each component of the alternative pathway (C3b, factor
B, properdin and factor Bb) were incubated for 30 min at
37 °C under agitation. Lastly, the wells were washed twice
with 200 μl PBS/tween-20 at room temperature for 2 min
under agitation.
To detect plate-bound C3b, properdin, factor B and
Bb, the wells were firstly incubated with primaryantibodies (rabbit anti-human C3b, goat anti-human
properdin, goat anti-human factor B and goat anti-
human Bb, respectively) diluted using a 1:5000 ratio,
followed by the addition of the secondary antibodies
(peroxidase-conjugated mice anti-rabbit IgG antibody
and peroxidase-conjugated rabbit anti-goat IgG antibody
at a dilution ratio of 1:3000). The components bound to
the plates were exposed by the addition of 200 μl of de-
veloping solution. The measurements and data analyses
were performed as described above.
ELISA for evaluation of the decay of factors of the
complement alternative pathway
ELISA assays were modified from a previously described
protocol [16]. 96-well microplates were coated with
0.1 % agarose at 37 °C for 24 h and were then incubated
with NHS in HMEBN solution at 37 °C for 30 min for
convertases formation. Wells were washed with HMEBN
solution and then incubated with 15 μg of salivary pro-
tein in HMEBN for 30 min at 37 °C. After incubation,
wells were again washed with HMEBN and the detection
of microplate-bound components (C3b, Bb, Properdin,
C5b or C9) was performed using primary specific anti-
bodies (rabbit anti-human C3b, goat anti-human Bb,
goat anti-human properdin, goat anti-human C5b or
goat anti-human C9) followed by a secondary peroxidase-
conjugated mice anti-rabbit IgG or rabbit anti-goat IgG,
both diluted in HN solution and incubated for 30 min at
room temperature. The development and percent depos-
ition of factors on microplates were analysed as described
above.
Membrane attack complex (MAC) deposition assessment
by haemolytic assay
Classical pathway haemolytic assays were carried out as
described in section 2.2 but using C6 (Comp tech:
A323), C7 (Comp tech: A324) or C8 (Comp tech: A325)
depleted serum diluted at 1:10 in GHB2+ [37]. Tubes
were then centrifuged at 480 g for three min at 4 °C and
erythrocytes were re-suspended in 300 μl of GHB-EDTA
solution and used in a second round of classical pathway
haemolytic assay with NHS under the same conditions
described on item 2.2.
On the first round, the complement system was acti-
vated and the components were deposited on the mem-
brane of erythrocytes up to the point where the absence
of the specific component under investigation halted the
progress of the pathway, ultimately preventing the for-
mation of the membrane attack complex (MAC). In the
second round, the component present in the NHS
(which was missing in the first round) resumes MAC
formation (except if MAC inhibitors are present in the
saliva) without a further activation of the classical path-
way which is blocked by EDTA.
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Statistical analysis was performed using GraphPad Prism
5.0 software. All experiments were performed with at
least three biological replicates in duplicate (haemolytic
assays) or triplicate (deposition assays). The difference
between groups was assessed using t-test (when compar-
ing two groups) and ANOVA followed by Dunnett’s or
Bonferroni post-hoc tests (when comparing more than
two groups). A 95 % significance level (P < 0.05) was set
as statistically significant.
Results
Rhipicephalus microplus saliva inhibits both the classical
and the alternative pathway
Saliva from fully-engorged females was tested for inhibi-
tory effects on the classical and alternative complement
pathways using haemolytic assays. The results are sum-
marized in Fig. 1a. Rhipicephalus microplus saliva was
able to inhibit both of these pathways of the human
complement system. This inhibition was dose-dependent:
5.09 μg was the amount of salivary proteins needed to in-
hibit 50 % of the classical pathway activity and 4.67 μg
was the amount of salivary proteins needed to inhibit
50 % of the alternative pathway activity.
Fully- and partially engorged females produced differ-
ent quantities and qualities of saliva when stimulated
with pilocarpine. The average volumes and concentra-
tion of salivary proteins collected per tick were: 8.58 μl
at 0.76 μg/μl (n = 55) and 1.52 μl at 1.89 μg/μl (n = 57)
from fully- and partially engorged females, respectively.
However, saliva from both engorgement phases pro-
duced a similar inhibitory effect on the classical (t-test:
t(4) = 1.27, P = 0.27) and alternative pathways (t-test:
t(4) = 0.19, P = 0.43) (Fig. 1b). As pilocarpine was used
to stimulate tick salivation, pilocarpine control assays
were carried out and showed no effect on either theFig. 1 Rhipicephalus microplus salivary inhibition of haemolysis by the class
the haemolytic assay. Human serum was added to assess the effects of sali
(12.5 μl) complement pathways, inducing at least 90 % of haemolysis. In (a
proteins was used. Bars represent the arithmetic mean ± standard deviation
non-significant (P > 0.05)classical or alternative pathways at 15, 30, 60 and 120 μg
(Additional file 1: Figure S1).
Rhipicephalus microplus saliva inhibits the deposition of
C4 by the classical pathway
To determine which component of the classical comple-
ment pathway is affected by R. microplus saliva, we first
adsorbed human IgG onto a 96-well microplate, then
added human serum to allow the deposition of comple-
ment components in the activation surface and their rec-
ognition by specific antibodies. Saliva was unable to
inhibit the deposition of C1q (repeated measures
ANOVA: F(4,10) = 10.61, P = 0.787), the first molecule of
the classical complement activation pathway, on the mi-
croplate surface (Fig. 2a). However, it inhibited the depos-
ition of C4b (repeated measures ANOVA: F(4,10) = 4.77,
P = 0.029, Fig. 2b) and all the subsequent factors such as
C3b (repeated measure ANOVA: F(4,10) = 6.86, P = 0.011,
Fig. 2c), C5b (repeated measures ANOVA: F(4,10) =
10.43, P = 0.003, Fig. 2d), and C9 (repeated measures
ANOVA: F(4,10) = 10.78, P = 0.003, Fig. 2e).
Rhipicephalus microplus saliva inhibits the cleavage of C4
by the classical pathway
Next, we investigated the mechanism underlying the
saliva-induced classical pathway inhibition. Since the in-
hibitory effect of saliva was first detected on the depos-
ition of C4b, the supernatant of haemolytic assays
activated by the classical pathway were evaluated by
Western blot with anti-C4 polyclonal antibodies. In the
control samples (containing serum, saline and erythro-
cytes incubated for 30 min), the anti-C4 antibodies
recognised the α (93 kDa), β (75 kDa) and γ (33 kDa)
subunits of C4 as well as the 84 kDa α’ fragment, which
is a product of C4 degradation. There was no α’ frag-
ment in the treatment samples (containing serum, salivaical and alternative pathways. A total volume of 125 μl was used for
va on the process of haemolysis via the classical (2.1 μl) and alternative
) different amounts of saliva were tested and in (b) 7.5 μg of salivary
(SD) from three biological replicates. Abbreviation; ns,
Fig. 2 Effect of Rhipicephalus microplus saliva on the deposition and cleavage of components of the classical pathway. a-e Deposition of C1q,
C4b, C3b, C5b and C9, respectively, on the activation surfaces. Bars represent the arithmetic mean ± standard deviation (SD) of three biological
replicates. Asterisks indicate a statistically significant difference compared to controls (*P < 0.05; **P < 0.01; ***P < 0.001). f Inhibition of C4 cleavage
through the classical pathway. Supernatant of haemolysis assays by classical pathway with salivary proteins (15 μg) or without saliva were
analysed by Western blot, which were probed with anti-C4 polyclonal antibodies. g Action of salivary proteins on C1s enzymatic activity. Assays
were carried out by combining purified C4 and C1s to saliva and C4 cleavage was analysed by Western blot. The α (93 kDa), β (75 kDa) and γ
(33 kDa) subunits of C4 as well as the α’ fragment (84 kDa) originated from C4 cleavage are indicated by arrows. Results of one Western blot out
of three are shown in g and f
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C4 cleavage (Fig. 2f ). As C4 is cleaved by C1s at the
classical pathway, we then investigated the action of sal-
iva on C1s. However, the presence of salivary proteins
did not affect the C1s-mediated cleavage of C4 (Fig. 2g).
Rhipicephalus microplus saliva inhibits the deposition of
C3b and fB by the alternative pathway
To determine which component of the alternative com-
plement cascade is affected by R. microplus saliva, we
first adsorbed agarose onto the surface of a 96-well mi-
croplate, then added human serum to allow the depos-
ition of complement components on the activation
surface and their recognition by specific antibodies.
Saliva significantly inhibited the deposition of C3b evenwhen small amounts of salivary proteins were used (re-
peated measures ANOVA: F(4,10) = 103.9, P < 0.001,
Fig. 3a). Consequently, all subsequent factors tested were
also significantly inhibited such as Bb (repeated mea-
sures ANOVA: F(4,10) = 29.26, P < 0.001, Fig. 3b) and P
(repeated measures ANOVA: F(4,10) = 32.12, P < 0.001,
Fig. 3c), both of which form the C3 convertase and C5b
(repeated measures ANOVA: F(4,10) = 43.76, P < 0.001,
Fig. 3d) and C9 (repeated measures ANOVA: F(4,10) =
51.07, P < 0.001, Fig. 3e), which are MAC components.
Rhipicephalus microplus saliva inhibits the cleavage of C3
and fB through the alternative pathway
The results above show that R. microplus saliva acts at
the initial stages of activation of the alternative pathway.
Fig. 3 Effect of Rhipicephalus microplus saliva on the deposition and cleavage of components of the alternative pathway. a-e Deposition of C3b,
Bb, properdin (P), C5b and C9, respectively, onto the activation surfaces. Bars represent the arithmetic mean ± standard deviation (SD) of three
biological replicates. Asterisks indicate statistically significant differences between experimental samples and controls (*P < 0.05; **P < 0.01; ***P
< 0.001). f, g Inhibition of C3 and factor B (fB) cleavage by the alternative pathway, respectively. The supernatant from the haemolysis assay
reactions via the alternative pathway or with salivary proteins (15 μg) or without saliva was analysed by Western blot, which was probed with
anti-C3 (f) or anti-fB (g) polyclonal antibodies. h Action of saliva on factor D enzymatic activity. Assays were carried out by combining purified fB,
C3b and factor D in the absence or presence of salivary proteins (15 μg) followed by Western blot analysis probed with anti-fB polyclonal anti-
bodies. In f, the α (110 kDa) and β (76 kDa) subunits of C3 as well as the 46 kDa fragment of the α chain are indicated by arrows. In g and h, fB
(93 kDa) and its cleavage product Bb (60 kDa) are indicated by arrows. Results of one Western blot out of three are shown in f-h
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evaluated the activity of the saliva on the C3 and fB
components. Alternative pathway haemolytic assays
were performed and the supernatant of the reactions
was evaluated by Western blot using anti-C3 and anti-fB
polyclonal antibodies.
In the control samples (containing serum, saline and
erythrocytes incubated for 30 min with the activation
surface), the anti-C3 antibodies confirmed the presence
of the α (110 kDa) and β (76 kDa) subunits as well as a
46 kDa band, which is the degradation product of the
C3 α chain, indicating cleavage of C3. The 46 kDa band
was not seen in the treatment samples (containing
serum, saliva and erythrocytes incubated for 30 min with
the activation surface), indicating that saliva inhibits the
production of C3b (Fig. 3f ). The presence of saliva inthe haemolytic assays also prevented the formation of
Bb from fB (Fig. 3g), suggesting that the saliva inhibits
the cleavage of fB. The production of Bb in an assay
where fB was combined to C3b, factor D (D) and saliva
indicates that saliva does not inhibit D-mediated cleav-
age of fB (Fig. 3h).
Rhipicephalus microplus saliva inhibits the binding of fB to
C3b through the alternative pathway
To assemble the C3 convertase (C3bBb) of the alterna-
tive pathway, fB must bind to C3b and then be cleaved
by factor D. Properdin stabilises the binding of C3b to
Bb. Therefore, we assessed the effects of R. microplus
saliva on the formation of the C3b-fB-properdin com-
plex. To this end, purified C3b was adsorbed onto the
surface of a 96-well microplate, and then fB and
Fig. 5 Binding of components from the alternative complement
pathway to the saliva of Rhipicephalus microplus. fB = factor B;
P = properdin; BSA = bovine serum albumin (control). Assays were
performed by adsorbing saliva (10 μg of salivary proteins) on a
96-well microplate followed by the addition of C3b, fB, properdin and
Bb purified components in the presence of Mg2+. The binding of
the components was assessed using specific polyclonal antibodies.
Bars represent the arithmetic mean ± standard deviation (SD) of
three biological replicates. Asterisks indicate significant difference
from controls (*P < 0.01; ***P < 0.001)
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(the precursor of C3 convertase) in the presence of Mg2+.
Deposition of the components was analysed using anti-fB
and anti-properdin polyclonal antibodies.
Saliva significantly reduced the binding of fB to C3b in
a dose-dependent manner (repeated measures ANOVA:
F(4,10) = 23.26, P < 0.001, Fig. 4a), however it was only
able to affect the binding of properdin to C3b when 15
μg of salivary proteins were added (repeated measures
ANOVA: F(4,10) = 3.92, P = 0.048, Fig. 4b). This shows
that saliva inhibits the alternative pathway by interfering
on the association of C3b and fB, thereby preventing the
formation of C3 convertase.
Rhipicephalus microplus saliva binds to C3b and properdin
but not to factor B to inhibit the alternative pathway
We coated 96-well microplates with saliva and incubated
them with complement components (C3b, factor B, Bb
and properdin) before adding specific antibodies to de-
tect which components of the complement alternative
pathway interact directly with saliva. As shown in Fig. 5,
the molecules present in saliva only bound significantly
to C3b (Bonferroni, t = 3.99, P < 0.01) and more strongly
to properdin (P) (Bonferroni, t = 7.94, P < 0.001).
Rhipicephalus microplus saliva does not remove C3
convertase components deposited on alternative
pathway activation surfaces
As shown in Figs. 4 and 5, saliva prevents the formation
of C3 convertase by inhibiting the deposition of compo-
nents that are part of this enzyme and the association of
fB and C3b. Thus, we investigated whether saliva is also
able to displace any of the C3 convertase components
(C3b, fB and properdin) deposited via the alternative
pathway. To this end, a 96-well microplate previously
coated with agarose was incubated for 30 min withFig. 4 Rhipicephalus microplus saliva inhibition upon the binding of factor B
performed by adsorbing purified C3b on a 96-well microplate followed by
Different amounts of saliva were tested. The deposition of the component
Bars represent the arithmetic mean ± standard deviation (SD) of three biolo
(*P < 0.05; **P < 0.01; ***P < 0.001)human serum before saliva and anti-C3, anti-fB and
anti-properdin polyclonal antibodies were added. We
found that saliva is not able to remove C3b, fB or pro-
perdin once these components of the alternative path-
way have been deposited on the activation surface
(Fig. 6).
Rhipicephalus microplus saliva does not inhibit deposition
of C6-8 or remove pre-deposited components of the MAC
The data presented above revealed that saliva acts at the
initial activation steps of the complement cascade. As
Jore et al. [17] have shown that saliva inhibits C5band properdin to C3b. fB = factor B (a); P = properdin (b). Assays were
the addition of purified fB and properdin in the presence of Mg2+.
s was assessed using anti-fB and anti-properdin polyclonal antibodies.
gical replicates. Asterisks indicate significant differences from controls
Fig. 6 Ability of Rhipicephalus microplus saliva to displace
complement alternative pathway factors already deposited.
Bb = factor Bb; P = properdin. Human serum was added to a
microplate pre-coated with agarose, leading to the formation of
C3 convertase. After 30 min, R. microplus saliva was added and the
presence of complement component deposits was evaluated using
anti-C3, anti-factor B and anti-properdin polyclonal antibodies. Bars
represent the arithmetic mean ± standard deviation (SD) from three
biological replicates. Statistically significant differences between samples
with and without saliva were assessed using t-test (C3b t(2) = 1.31,
P = 0.32; Bb t(2) = 1.99, P = 0.18; P t(2) = 3.33, P = 0.09). Abbreviation:
ns, non-significant (P > 0.05)
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directly on other components of the final stages of the
complement pathway (mainly MAC components). To
this end, we performed classical pathway haemolytic as-
says using sera depleted of one of the following MAC
components: C6, C7 or C8. These sera allowed us to in-
vestigate the activation of the complement cascade up toFig. 7 Effect of Rhipicephalus microplus saliva on the membrane attack com
components’ deposition: classical pathway-induced haemolysis was allowe
C6-, C7- or C8-depleted serum, respectively. Normal human serum containi
to resume. Haemolysis levels were evaluated in each tube. b Effect on MAC c
formation was allowed to occur in agarose-coated 96-well microplates. At thi
evaluated using anti-C5b and anti-C9 polyclonal antibodies. Bars represent th
a Dunnet (C6 F(2,6) = 2.32, P = 0.21; C7 F(2,6) = 0.32, P = 0.75; C8 F(2,6) = 3.30,
Abbreviation: ns, non-significant (P > 0.05)the deposition of the C5b, C6 and C7 components, re-
spectively. Normal human serum containing EDTA was
then added to the assay to resume the complement cas-
cade without new complement activation, as EDTA che-
lates Ca2+ and Mg2+ ions. Inhibition of haemolysis
would indicate that saliva could be acting upon each
MAC component. However, haemolysis did take place in
the treatment samples, suggesting that saliva does not
impair the deposition of C6, C7 and C8 on the activation
surface (Fig. 7a).
Next, we evaluated whether saliva is also able to dis-
place any of the MAC components (C5b and C9) already
deposited on the activation surface via the alternative
pathway. To this end, a 96-well microplate coated with
agarose was incubated for 30 min with human serum be-
fore saliva and anti-C5b and anti-C9 polyclonal anti-
bodies were added. Saliva is not able to remove neither
C5b nor C9 after these components of the alternative
pathway have already been deposited on the activation
surface (Fig. 7b). Indeed, the presence of C9 on the acti-
vation surface indicates none of the previous compo-
nents of MAC were removed.
Discussion
The huge economic and health impacts in the cattle in-
dustry caused by R. microplus has fostered research on
how these ticks modulate host’s immune system so that,
ultimately, therapeutic strategies could be developed
against these ectoparasites. It is well known that many
tick species use bioactive molecules present in their sal-
iva to inhibit the complement system [8–11]. However,
in spite of their importance, only one R. microplusplex (MAC) components’ deposition and removal. a Effect on MAC
d to take place up to the point of C5, C6 or C7 deposition using
ng EDTA was then added to the assay to allow the haemolytic process
omponents’ removal: alternative complement pathway-induced MAC
s point, saliva was added and the presence of MAC components was
e arithmetic mean ± standard deviation (SD) of three biological replicates.
P = 0.14) and b t-test (C5b t(2) = 3.68, P = 0.07; C9 t(2) = 1.82, P = 0.21).
Silva et al. Parasites & Vectors  (2016) 9:445 Page 11 of 14salivary protein has been shown to affect the comple-
ment cascade [17]. The current study demonstrated that
R. microplus saliva has other complement inhibitors able
to block both the classical and the alternative pathways.
Taken together, our results show that ticks have comple-
ment inhibitors acting on different points of the cascade,
reinforcing the hypothesis that complement inhibition
may be extremely important for tick’s success.
The inhibition of both pathways makes the anti-
complement activity present in R. microplus saliva different
from that observed on ticks of the extensively studied genus
Ixodes. Indeed, most of the Ixodes species with complement
inhibition activity do so only through the alternative
pathway, with both alternative and lectin pathways
affected in only one tick species [10].
Saliva of partially and fully-engorged females induced
similar levels of haemolysis inhibition when either the
classical or alternative pathways were activated. In I. rici-
nus, inhibition of the alternative pathway has been
present in the saliva at both engorgement stages al-
though the levels of inhibition observed at the end of
feeding were higher than those reported herein for R.
microplus [43, 44].
The volume and concentration of the salivary proteins
were remarkably different between the stages of en-
gorgement. Fully-engorged females produced approxi-
mately six times more saliva than partially engorged
ones. However, the protein concentration of the saliva
produced by the partially engorged females was consid-
erably higher compared to the saliva produced by fully-
engorged females. This finding is in accordance to that
reported in Tirloni et al. [45]. However, we found that
the volume of saliva secreted at both stages of engorge-
ment was approximately 10 times greater than that re-
ported by these authors. These differences in volume of
saliva production may be related to the time between
the detachment of ticks from the host and pilocarpine
stimulation or due to environmental conditions such as
temperature and average relative humidity [46].
Here we showed that R. microplus saliva blocks the
initial steps of the classical pathway. Indeed, saliva did
not affect C1q deposition but prevented the deposition
of C4b, as confirmed by the data showing that the cleav-
age of C4 into C4b was blocked. Taken together, these
results indicate that inhibition of the classical pathway
occurs by preventing the cleavage of C4 by C1s and,
hence, the formation of C4b. Saliva was not able to block
C1s enzymatic activity. Therefore the possible inhibition
mechanism could act preventing C4 binding to the as-
sembled C1, displacing the serine proteases from the C1
complex or directly inhibiting C1r activity. However, fur-
ther research is required to investigate these hypotheses
and improve our understanding on how R. microplus
saliva inhibits the classical pathway.To our knowledge, this is the first study showing in-
hibition of the early steps of the classical complement
cascade by the saliva of an ixodid tick. Previous studies
on R. microplus and other ixodid ticks showed inhibition
of the final steps of the cascade [17]. Similar data are
only available for other haematophagous arthropods,
which also showed saliva-induced inhibition of the clas-
sical pathway at the initial stages. Indeed, Triatoma bra-
siliensis saliva prevented the deposition of C4b onto the
activation surface [38] and molecules present in Lutzo-
myia longipalpis saliva prevented C4 cleavage and C4b
deposition [47].
In haemathophagous animals, inhibition of the clas-
sical pathway has been shown to involve a mechanism
mediated by calreticulin. In helminths, such as Necator
americanus and Haemonchus contortus, calreticulin se-
questrates C1q and prevents its binding to antibodies,
thereby blocking the classical pathway [48, 49]. Interest-
ingly, calreticulin is also expressed in the saliva of several
tick species [50–52] including R. microplus [53]. How-
ever, although calreticulin from R. microplus saliva has
been shown to bind C1q, it did not inhibit the progres-
sion of the classical complement pathway [52].
The anticomplement activity described in the saliva of
Ixodes ticks acts through the alternative pathway by inhi-
biting C3 convertase formation. This activity is based on
the binding of the salivary active molecule to properdin
and its removal from C3 convertase. In the absence of
properdin, C3 convertase half-life is significantly short-
ened leading to a reduction in C3 convertase levels,
thereby inhibiting the progression of the alternative
pathway [15, 16].
The saliva of R. microplus also inhibited the haemoly-
sis of rabbit erythrocytes mediated by the alternative
pathway. We found that inhibition of the alternative
pathway is related to the direct binding of R. microplus
salivary protein(s) to C3b and properdin. The reduced
deposition of C3b on wells covered with agarose was
probably a consequence of the lack of formation of C3
convertase. Saliva does not block factor D activity, but it
is plausible to suggest that binding of saliva to C3b and
to properdin prevents the association of fB to C3b and,
to a lesser extent, of properdin to C3 convertase thereby
blocking the activation of the alternative pathway.
Rhipicephalus microplus saliva did not remove any of
the components of C3 convertase, once it was assem-
bled. This is a characteristic of the alternative pathway
inhibitory activity found specifically in R. microplus sal-
iva because the inhibition promoted by Ixodes anti-
complement molecules directly removes pre-bound pro-
perdin and indirectly removes pre-bound Bb [15, 16].
These results suggest that R. microplus salivary anti-
complement activity is attributed to a novel molecule
with a different mechanism of action from that found in
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These data highlight the differences between the salivary
activities of blood-sucking arthropods that, in the face of
complexity, need to overcome similar anti-tick defence
mechanisms of their hosts and ensure feeding success
[54]. This hypothesis is supported by analyses of R.
microplus databases that did not yield any significant
hits to known complement inhibitors from Ixodes ticks
(SALP20, IxACs, IRACs and ISACs).
The action of salivary inhibitors in the early stages of
the complement cascade is highly efficient for the ticks:
the saliva acts before the amplification of the comple-
ment signal which means that considerably fewer saliv-
ary molecules will be required to completely block the
pathways. The inhibition of C3 convertase assemblage
reduces the number of salivary molecules opsonised by
C3b and prevents the presentation of these molecules to
the host’s immune system [38]. Moreover, without the
production of C3b and C5b, inflammatory mediators
(such as C3a and C5a) cannot be produced at the bite
site, and inflammation can be prevented. Absence of
C3a may preclude homeostasis at the bite site since it
also induces platelet activation and aggregation [55].
Rhipicephalus microplus saliva was previously shown
to affect C5b deposition [17]. Here we demonstrated
that it has no effect in C6, C7 or C8 deposition and in
the removal of C5b or C9, deposited on the activation
surface. Inhibition of C5b formation was also observed
in argasid ticks for the OMCI, a salivary lipocalin of O.
moubata [33]. Those molecules bind specifically to C5
thereby preventing its cleavage into C5b and C5a by C5
convertases [17, 32]. Binding to C5 leads to an efficient
complement inhibition mechanism because it blocks all
activation pathways at once. However, the number of C5
molecules to be inhibited would be considerably high,
since the cascade would have been already partially
amplified with several inflammatory mediators produced,
especially C3a.
Conclusions
Here we confirmed the presence of anti-complement ac-
tivity in the saliva of R. microplus and showed the mecha-
nisms by which it inhibits the early steps of classical and
alternative pathways. Saliva acts strongly at the initial steps
of both complement activation pathways by blocking the
C4 cleavage and deposition of C4b on the alternative path-
way activation surface. In the alternative pathway, saliva
acts by binding to initial components of the cascade (C3b
and properdin) thereby preventing the C3 convertase for-
mation reducing C3b production and deposition. Rhipice-
phalus microplus saliva is not able to remove C3 convertase
components deposited on alternative pathway activation
surfaces and has no action on the formation or decay of
the C6, C7 and C8 components of the MAC.We suggest that this inhibitory activity is an important
strategy performed by this tick species to modulate
host’s immune system. Further research is currently be-
ing carried out to identify bioactive agent(s) responsible
for the complement inhibitory activity present in R.
microplus saliva as these molecules may be potential
therapeutic targets to reduce the burden of these ecto-
parasites on cattle farming.
Additional file
Additional file 1: Figure S1. Effect of pilocarpine on haemolysis by the
classical and alternative pathways. Different concentrations of pilocarpine
were tested using normal human serum via the classical (a) and
alternative (b) complement pathways, inducing at least 90 % of
haemolysis. Bars represent the arithmetic mean ± standard deviation (SD)
of three biological replicates. (TIF 384 kb)
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